Savara Inc. (SVRA)
$
2.28
+0.04 (1.75%)
Key metrics
Financial statements
Free cash flow per share
-0.4425
Market cap
335.3 Million
Price to sales ratio
1.2 Thousand
Debt to equity
0.1997
Current ratio
14.9138
Income quality
0.9360
Average inventory
0
ROE
-0.6588
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Savara Inc., a clinical-stage biopharmaceutical company headquartered in Austin, Texas, focuses on rare respiratory diseases with its lead product candidate, molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, currently in Phase III development for the treatment of autoimmune pulmonary alveolar proteinosis. In its latest financial reporting, the company reported an income before tax of -$95,881,000.00 showcasing its pre-tax profitability. Additionally, Savara earned an interest income of $6,467,000.00 highlighting its financial investments. However, the cost of revenue for the company is $0.00 indicating its production and operational expenses. The company reported a net loss of -$95,881,000.00 which reflects ongoing challenges in its operations, and the weighted average number of diluted shares outstanding is 198,191,936.00 which points to the potential dilution effects on its shareholders. In the market landscape, the stock is affordable at $2.24 making it suitable for budget-conscious investors. With a high average trading volume of 1,503,331.00 it indicates strong liquidity, allowing for ease of buying and selling shares. Savara has a market capitalization of $394,068,360.00 classifying the company as a small-cap player within the industry. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape. Furthermore, it belongs to the Healthcare sector, driving innovation and growth in a segment that is crucial for addressing unmet medical needs.
Is Savara Inc. (SVRA) a good investment?
Investing in Savara Inc. (SVRA) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C-, with a Bearish outlook. Always conduct your own research before investing.
What is Savara Inc. (SVRA)'s stock forecast?
Analysts predict Savara Inc. stock to fluctuate between $1.89 (low) and $5.11 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Savara Inc.'s market capitalization?
As of 2025-05-30, Savara Inc.'s market cap is $394,068,360, based on 172,837,000 outstanding shares.
How does Savara Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Savara Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Savara Inc. (SVRA) stock?
To buy Savara Inc. (SVRA) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for SVRA. Place an order (Market, Limit, etc.).
What is the best time to invest in Savara Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has Savara Inc. stock ever split?
Savara Inc.'s last stock split was 1:70 on 2017-04-28.
How did Savara Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$0.48 | Growth: 45.45%.
Where can I find Savara Inc.'s investor relations reports?
Visit https://www.savarapharma.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Savara Inc.?
You can explore historical data from here
What is the all-time high and low for Savara Inc. stock?
All-time high: $5.70 (2024-03-05) | All-time low: $1.02 (2022-02-24).
What are the key trends affecting Savara Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / May 30, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Savara Inc. ("Savara Inc.") (NASDAQ:SVRA) concerning possible violations of federal securities laws. On May 27, 2025, the company announced that the FDA issued a Refusal to File letter for its Biologics License Application for Molbreevi, its lead drug candidate for autoimmune PAP.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / May 28, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Savara Inc. ("Savara Inc.") (NASDAQ:SVRA) concerning possible violations of federal securities laws. On May 27, 2025, the company announced that the FDA issued a Refusal to File letter for its Biologics License Application for Molbreevi, its lead drug candidate for autoimmune PAP.
globenewswire.com
NEW YORK, May 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Savara Inc. (“Savara” or the “Company”) (NASDAQ: SVRA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / May 28, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Savara Inc. ("Savara Inc.") (NASDAQ:SVRA) concerning possible violations of federal securities laws. On May 27, 2025, the company announced that the FDA issued a Refusal to File letter for its Biologics License Application for Molbreevi, its lead drug candidate for autoimmune PAP.
accessnewswire.com
BOSTON, MA / ACCESS Newswire / May 28, 2025 / Block & Leviton is investigating Savara Inc. (Nasdaq:SVRA) for potential securities law violations. Investors who have lost money in their Savara Inc. investment should contact the firm to learn more about how they might recover those losses.
globenewswire.com
Block & Leviton is investigating Savara Inc. (Nasdaq: SVRA) for potential securities law violations. Investors who lost money should contact the firm.
businesswire.com
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to five new employees. On May 21, 2025, the Compensation Committee of Savara's Board of Directors granted the inducement awards to five new employees who recently joined the Company. The inducement awards consist of options to purchase an aggregate of 85,000 shares of the Company's common stock and restricted.
businesswire.com
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, today announced new data in two poster presentations at the ATS International Conference 2025. Data presented were from the Phase 3 IMPALA-2 clinical trial of molgramostim in aPAP and demonstrated that molgramostim reduces surfactant burden and improves health-related quality of life outcomes in patients with aPAP. ATS 2025 Posters Poster Ti.
seekingalpha.com
Savara, Inc. focuses exclusively on developing its sole therapeutic product, MOLBREEVI. Its investment thesis highlights the potential of MOLBREEVI to address unmet medical needs in autoimmune pulmonary alveolar proteinosis (aPAP). Rating justification: Strong clinical data, multiple FDA designations and a clear path to regulatory approval make Savara a compelling investment opportunity.
businesswire.com
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to seven new employees. On April 9, 2025, the Compensation Committee of Savara's Board of Directors granted the inducement awards to seven new employees who recently joined the Company. The inducement awards consist of options to purchase an aggregate of 107,000 shares of the Company's common stock and restri.
See all news
